Abstract
The increasing resistance of Mycobacterium tuberculosis to the existing drugs has alarmed the worldwide scientific community. In an attempt to overcome this problem computer-aided drug design has provide an extraordinary support to the different strategies in drug discovery. There are around 250 biological receptors such as enzymes that can be used in principle, for the design of antituberculosis compounds that act by a specific mechanism of action. Also, there more than 5000 compound available in the literature, and that constitute important information in order to search new molecular patterns for the design of new antituberculosis agents. The purpose of this paper is to explored the current state of drug discovery of antituberculosis agents and how the different strategies supported by computeraided drug design methods has influenced in a determinant way in the design of new molecular entities that can result the future antituberculosis drugs.
Keywords: Structure based-drug design, ligand based-drug design, enzymatic inhibitors, 3D-QSAR methodologies, graph-theoretical approaches, computer-aided drug design, antituberculosis, MDR-TB, Artificial Neural Networks (ANN), ANTI-TB AGENTS, CoMSIA methods, CoMFA methods, MIC, Heterogeneous Series, Mycobacterium tuberculosis, QSPR, QSTR, Multiple Linear Regression, Hydropathic Interactions, CP-MLR
Current Pharmaceutical Design
Title: Current Pharmaceutical Design of Antituberculosis Drugs: Future Perspectives
Volume: 16 Issue: 24
Author(s): Alejandro Speck-Planche, Marcus Tulius Scotti and Vicente de Paulo-Emerenciano
Affiliation:
Keywords: Structure based-drug design, ligand based-drug design, enzymatic inhibitors, 3D-QSAR methodologies, graph-theoretical approaches, computer-aided drug design, antituberculosis, MDR-TB, Artificial Neural Networks (ANN), ANTI-TB AGENTS, CoMSIA methods, CoMFA methods, MIC, Heterogeneous Series, Mycobacterium tuberculosis, QSPR, QSTR, Multiple Linear Regression, Hydropathic Interactions, CP-MLR
Abstract: The increasing resistance of Mycobacterium tuberculosis to the existing drugs has alarmed the worldwide scientific community. In an attempt to overcome this problem computer-aided drug design has provide an extraordinary support to the different strategies in drug discovery. There are around 250 biological receptors such as enzymes that can be used in principle, for the design of antituberculosis compounds that act by a specific mechanism of action. Also, there more than 5000 compound available in the literature, and that constitute important information in order to search new molecular patterns for the design of new antituberculosis agents. The purpose of this paper is to explored the current state of drug discovery of antituberculosis agents and how the different strategies supported by computeraided drug design methods has influenced in a determinant way in the design of new molecular entities that can result the future antituberculosis drugs.
Export Options
About this article
Cite this article as:
Speck-Planche Alejandro, Tulius Scotti Marcus and de Paulo-Emerenciano Vicente, Current Pharmaceutical Design of Antituberculosis Drugs: Future Perspectives, Current Pharmaceutical Design 2010; 16 (24) . https://dx.doi.org/10.2174/138161210792389289
DOI https://dx.doi.org/10.2174/138161210792389289 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Anti-Tuberculosis Drugs in Clinical Development: An Overview
Current Bioactive Compounds Chemistry and Pharmacology of Neglected Helminthic Diseases
Current Medicinal Chemistry Characterization of pDNA-TMC Nanoparticle Interaction and Stability
Current Drug Delivery Controlled Delivery of Biotechnological Products
Current Pharmaceutical Biotechnology Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Synthesis, Spectroscopic and Structural Studies of New 2-Substituted 4- Nitroimidazoles
Letters in Organic Chemistry Stopping of the Downtrend of Tuberculosis in Iran, a Systematic Review of Associated Risk Factors
Infectious Disorders - Drug Targets Understanding Mass Spectrometry-based Global Mycobacterial Lipidomics
Current Molecular Medicine The Clinical Relevance of Differential Cell Counts in Induced Sputum and its Relationship with Various forms of Asthma
Current Respiratory Medicine Reviews The Potent Antiplasmodial Calmodulin-Antagonist Trifluoperazine Inhibits Plasmodium falciparum Calcium-Dependent Protein Kinase 4
Protein & Peptide Letters Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Current Pharmaceutical Design Anti-Tuberculosis Drug Induced Hepatotoxicity and Genetic Polymorphisms in Drug-metabolizing Genes
Current Pharmacogenomics Recent Patents Regarding Essential Oils and the Significance of their Constituents in Human Health and Treatment
Recent Patents on Anti-Infective Drug Discovery Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Synthesis and Biological Activity of 2,7-Naphthyridine Derivatives: An Overview
Current Organic Chemistry The Last Decade of Carbon Paste Electrodes in DNA Electrochemistry
Current Analytical Chemistry A Review Exploring Therapeutic Worth of 1,3,4-Oxadiazole Tailored Compounds
Mini-Reviews in Medicinal Chemistry Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort
Current HIV Research Molecular Dynamics Assisted Mechanistic Insight of Val430-Ala Mutation of Rv1592c Protein in Isoniazid Resistant <i>Mycobacterium Tuberculosis</i>
Current Computer-Aided Drug Design